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Abstract
Background: Whether the delivery of a large-for-gestational-age (LGA) infant predicts future maternal metabolic
syndrome (MetS) is not known. To this aim, we investigated the incidence of MetS and its components in women
with or without a history of gestational diabetes mellitus (GDM) with a view to the birth weight of the offspring.
Methods: Eight hundred seventy six women treated for their pregnancies in Kuopio University Hospital in 1989–
2009 underwent a follow-up study (mean follow-up time 7.3 (SD 5.1) years), of whom 489 women with GDM and
385 normoglycemic controls. The women were stratified into two groups according to the newborn’s birth weight:
10-90th percentile (appropriate-for-gestational-age; AGA) (n = 662) and > 90th percentile (LGA) (n = 116). MetS and
its components were evaluated in the follow-up study according to the International Diabetes Federation criteria.
Results: LGA vs. AGA delivery was associated with a higher incidence of MetS at follow-up in women with a background
of GDM (54.4% vs. 43.6%), but not in women without GDM.
Conclusion: An LGA delivery in women with GDM is associated with a higher risk of future MetS and this group is
optimal to study preventive measures for MetS. In contrast, an LGA delivery after a normoglycemic pregnancy was not
associated with an increased future maternal MetS risk.
Keywords: Gestational diabetes mellitus, Metabolic syndrome, Large-for-gestational-age, Birth weight
Background
Gestational diabetes mellitus (GDM) increases the risk of
obstetric complications, largely due to fetal overgrowth. In
addition, GDM is associated with an increased risk of de-
veloping type 2 diabetes (T2DM) [1–3], metabolic syn-
drome (MetS) and cardiovascular diseases (CVD) [4–8]
after the pregnancy. The key pathophysiological defects
underlying the increased cardiometabolic morbidity after
GDM pregnancy include chronic insulin resistance and
impaired insulin secretion, together with visceral obesity,
hypertension and dyslipidemia [9]. Disturbance in glucose
metabolism is considered to be a major cause for a
large-for-gestational-age (LGA) delivery [10], albeit many
environmental and genetic factors are also likely to play a
role. In particular, maternal pre-pregnancy body mass
index (BMI) and gestational weight gain have been shown
to be independent determinants of the infant birth weight
[11–13]. Women with pre-pregnancy overweight and
obesity were at 1.5-fold and 2-fold increased risk of deliv-
ery of an LGA infant, respectively [12]. Furthermore,
maternal metabolic factors including decreased high-density
lipoprotein (HDL) cholesterol, increased triglycerides [14]
and insulin have previously been shown to be independent
determinants of fetal macrosomia [15]. In continuum, infant
born LGA and exposed to an intrauterine environment of
diabetes or maternal obesity have also been shown to be at
an increased risk of developing MetS later in their lives [16].
We therefore hypothesized that a previous LGA deliv-
ery would be associated with an increased risk of
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incident MetS in the mother after the pregnancy. To this
aim, we investigated the incidence of MetS and its com-
ponents in women with and without GDM by groups of
different birth size.
Methods
This hospital register-based cohort study included women
whose pregnancies were treated in Kuopio University Hos-
pital, Finland, in 1989–2009. Women who had the diagno-
sis of GDM and a random sample of normoglycemic
women, both groups with completed oral glucose tolerance
test (OGTT) during pregnancy, were contacted by a letter
and invited for the study. A total of 489 women with GDM
and 385 women with normal OGTT result during preg-
nancy attended the follow-up study. 1234 women did not
reply or declined to participate in the study.
The women with and without GDM were classified based
on the birth weight of the newborn: between 10-90th per-
centile (appropriate-for-gestational-age; AGA) (n = 662) and
over 90th percentile (LGA) (n = 116). The women without
GDM and delivery of an AGA infant served as a control
group. In this study, LGA was defined as sex-specific birth
weight for gestational age above the 90th percentile on the
current Finnish newborn growth charts [17].
Data collection during pregnancy
In Finland, cost-free maternity care is offered to all preg-
nant women. The women considered to be at risk of
GDM underwent 2-h OGTT (75 g glucose after overnight
fasting) between the 24th and 28th weeks of gestation if
one or more following factors were present: age over
40 years, BMI ≥ 25 kg/m2, prior GDM or a history of a
macrosomic delivery, glucosuria, suspected fetal macroso-
mia in the current pregnancy. The diagnostic criteria of
GDM were as follows: until September 2001 the lower
limits of abnormal fasting, 1-h and 2-h capillary
whole-blood glucose 4.8, 10.0 and 8.7 mmol/l and since
September 2001 the lower limits of fasting, 1-h and 2-h
capillary plasma glucose 4.8, 11.2 and 9.9 mmol/l as per
contemporary guidelines. For the women with more than
one delivery during the study period, the first pregnancy
with an abnormal OGTT result was selected as the index
pregnancy. The women with GDM were seen regularly in
the Prenatal Outpatient Clinic in Kuopio University Hos-
pital and they received dietary advice, regular blood glu-
cose monitoring and insulin treatment when necessary.
The hospital register included data on maternal character-
istics and pregnancy risk factors, complications, pregnancy
outcome, and on the neonatal period of the offspring. The
women with overt T2DM at the time of pregnancy or type
1 diabetes mellitus (T1DM) diagnosed after the index
pregnancy, and those with a multiple pregnancy were ex-
cluded to eliminate confounding factors.
The follow-up study
The participants were recruited to the follow-up study be-
tween 2006 and 2009. The women underwent laboratory
tests, body composition and blood pressure measure-
ments, and answered questionnaires concerning their
family history and health behavior. All participants under-
went a 2-h OGTT (75 g of glucose). MetS was diagnosed
by waist circumference ≥ 80 cm, and at least two of the
following four criteria in accordance with the Inter-
national Diabetes Federation (IDF) 2005 criteria [18]:
blood pressure ≥ 130/85 mmHg, fasting plasma glucose
≥5.6 mmol/l, serum triglycerides ≥1.7 mmol/l, and HDL
cholesterol ≤1.29 mmol/l. These criteria were selected
since they are similar to the current care guidelines of
MetS in Finland. The women using medication for hyper-
glycemia, hypertension or dyslipidemia were included in
the analysis for the components of MetS.
Height was measured to the nearest 0.5 cm and weight to
the nearest 0.1 kg. Body mass index (BMI) was calculated
as weight (kg) divided by the height (m) squared. Waist cir-
cumference (at the midpoint between the lateral iliac crest
and the lowest rib) was measured to the nearest 0.5 cm.
Laboratory determinations
Plasma glucose was measured by an enzymatic hexokinase
photometric assay (Konelab Systems reagents; Thermo
Fischer Scientific, Vantaa, Finland). LDL-cholesterol, HDL-
cholesterol and total triglycerides were measured by
enzymatic colorimetric tests (Konelab Systems reagents).
Statistical analyses
The statistical analyses were conducted using SPSS ver-
sion 23 (SPSS Inc., Chicago, IL). P < 0.05 was considered
statistically significant. The results were given as the mean
± SD or number of cases and percentages. Statistical dif-
ferences in categorical variables between the study and
comparison groups were evaluated using the χ2 test.
Anthropometric and biochemical continuous variables
were analyzed using Student’s t-test, and log-transformed
variables were used to correct for their skewed distribu-
tion when appropriate. Since the diagnosis of GDM was
based on slightly different criteria depending on the origin
of the blood during the data collection, a correlation coef-
ficient was used to convert all values to correspond
venous plasma levels. The correlation coefficient was
based on the information from the Department of Clinical
Chemistry at Kuopio University Hospital.
This study was approved by the local Ethics Commit-
tee of the Kuopio University Hospital in accordance with
the Helsinki Declaration.
Results
The clinical characteristics of the study groups stratified
according to the birth weight of the offspring in index
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pregnancy and at the follow-up are shown in Table 1.
Women with GDM were older in both birth weight
categories as compared to controls during the index
pregnancy. Women in both GDM groups and the
women without GDM but with an LGA delivery were of
higher weight and more frequently multiparous than the
controls. Women with LGA infants had more frequently
a history of prior child’s birth weight over 4000 g as
compared to than those with AGA offspring.
Furthermore, women with GDM and an LGA delivery
had more often a prior spontaneous abortion. The study
groups did not differ in the rate of prior cesarean
section. The incidence of pre-eclampsia was higher in
women with GDM. No significant differences were
observed in gestational age at birth between the study
groups.
At the time of the follow-up study, the women with
GDM in both birth weight categories had shorter
follow-up time. However, no difference in the mean age
of the women was observed between the study groups.
The women with GDM and the ones without GDM but
with an LGA delivery were of higher weight than the
controls, although the study groups did not differ in
weight gain during the follow-up time (Table 1).
The comparison of cardiovascular and metabolic pa-
rameters of the study groups at follow-up is shown in
Table 2. The women with GDM in both birth weight
groups and the women without GDM with an LGA de-
livery had significantly higher waist circumference than
the control group; approximately 80% of the women in
those three groups reached the 80 cm waist circumfer-
ence limit. Both GDM groups had significantly lower
HDL levels and higher fasting plasma glucose than the
control group, with approximately 50% of the women
with GDM exceeding the limit 5.6 mmol/l at the
follow-up visit. The mean triglyceride levels were higher
in women with GDM in both birth weight categories.
However, the study groups did not differ significantly
concerning the triglyceride level over 1.7 mmol/l re-
quired for MetS criterion. No significant differences
Table 1 Clinical characteristics of the controls and GDM subjects in index pregnancy and at the follow-up study stratified according
to the offspring’s birth weight
Offspring’s birth weight AGA (10-90th percentile) LGA (>90th percentile)
Mean ± SD or % Mean ± SD or %
No GDM GDM No GDM GDM
(Controls) (Group 1) (Group 2) (Group 3)
Number of subjects 286 376 48 68
At the index pregnancy
Age (yrs) 29.5 ± 5.4 31.8 ± 6.0** 30.6 ± 5.0 32.6 ± 6.3**
Primiparity (%) 53.0 35.0** 34.1* 22.2**
Pre-pregnancy BMI (kg/m2) 23.8 ± 3.8 26.4 ± 5.0** 25.7 ± 3.5* 26.7 ± 4.1**
Family history of diabetes (%) 69.4 81.4** 75.0 80.9
Prior child’s birth weight > 4000 g (%) 25.4 25.6 43.8* 60.4**
Prior spontaneous abortion (%) 16.8 19.9 18.8 35.3*
Prior cesarean section (%) 5.9 9.6 16.7 7.4
Gestational age (d) 280 ± 11 279 ± 9 279 ± 11 278 ± 8
Pre-eclampsia (%) 1.4 5.3* 2.1 5.9*
Birth weight (g) 3595 ± 385 3596 ± 406 4365 ± 424** 4421 ± 370**
Placental-fetal mass ratio (%) 17.1 ± 3.0 17.5 ± 3.0 20.6 ± 15.8** 17.9 ± 2.5*
Low Apgar score 1 min < 7 (%) 1.7 5.9* 6.3 4.4
At the follow-up study
Follow-up time (yrs) 8.5 ± 5.5 5.3 ± 4.3** 7.4 ± 5.4 6.2 ± 4.9*
Age at follow-up (yrs) 38.4 ± 6.4 37.4 ± 7.2 38.3 ± 5.8 39.1 ± 7.5
BMI (kg/m2) 26.5 ± 4.9 28.3 ± 5.7** 27.9 ± 4.8* 29.2 ± 4.9**
Weight gain during the follow-up
time (kg)
5.7 ± 7.6 3.6 ± 7.9 4.3 ± 7.6 5.6 ± 9.3
GDM gestational diabetes mellitus, BMI body mass index, AGA appropriate for gestational age, LGA large for gestational age
All groups compared to controls separately
*p < 0.05
**p < .0001
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were observed in total blood pressure between the study
groups, even though the mean systolic blood pressure in
both GDM groups and diastolic pressure in the women
with GDM and LGA infants was significantly higher as
compared to controls (Table 2).
The incidence of MetS at the follow-up study stratified
with the birth weight of the offspring is illustrated in Fig. 1.
The incidence of MetS was higher in women with GDM
and an LGA (54.4%) than an AGA delivery (43.6%). Fur-
thermore, the incidence of MetS in LGA study groups was
three times higher in women with GDM as compared to
the normoglycemic women. However, the incidence of
MetS did not differ significantly in the non-GDM group be-
tween the AGA (24.5%) and LGA (18.8%) groups.
Table 2 The components of the metabolic syndrome (MetS) in the study subjects at the follow-up study stratified according to the
offspring’s birth weight
Offspring’s birth weight AGA (10-90th percentile) LGA (>90th percentile)
Mean ± SD or % Mean ± SD or %
No GDM GDM No GDM GDM
(Controls) (Group 1) (Group 2) (Group 3)
Number of subjects 286 376 48 68
Waist circumference (cm) 85.3 ± 11.6 91.0 ± 13.8** 88.8 ± 10.8* 94.2 ± 12.9**
Waist circumference ≥ 80 cm (%) 64.0 77.6** 81.3* 89.7**
Fasting glucose (mmol/l) 5.3 ± 0.4 5.6 ± 0.8** 5.4 ± 0.4 5.8 ± 0.8**
Fasting glucose ≥5.6 mmol/l (%) 25.2 46.8** 29.2 58.8**
Triglycerides (mmol/l) 1.0 ± 0.6 1.1 ± 0.6* 0.9 ± 0.4 1.2 ± 0.5*
Triglycerides ≥1,70 mmol/l (%) 10.6 15.2 4.2 16.2
HDL cholestrol (mmol/l) 1.5 ± 0.4 1.4 ± 0.4** 1.6 ± 0.3 1.3 ± 0.3**
HDL cholestrol < 1.29 mmol/l (%) 28.3 44.1** 20.8 57.4**
Systolic pressure (mmHg) 122.5 ± 14.3 125.8 ± 14.1* 121.4 ± 10.1 128.4 ± 14.2*
Diastolic pressure (mmHg) 78.3 ± 9.6 79.3 ± 9.2 77.5 ± 7.5 81.3 ± 10.0*
Blood pressure≥ 130/≥85 mmHg (%) 34.3 38.8 27.1 45.6
Metabolic syndrome (IDF) (%) 24.5 43.6** 18.8 54.4**
GDM gestational diabetes mellitus, BMI body mass index, AGA appropriate for gestational age, LGA large for gestational age
All groups compared to controls separately
*p < 0.05
**p < .0001
Fig. 1 The incidence of the metabolic syndrome among the study groups at the follow-up visit according to the birth weight of the newborn
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Discussion
Our long-term study indicated that after an LGA deliv-
ery, the incidence of MetS is three times higher in
women with GDM compared to those without GDM.
Increased waist circumference was the only component
of MetS in the non-GDM LGA group that was more
prevalent than in the control group. Among the women
with GDM, the limits of MetS in fasting glucose and
HDL cholesterol were broken more often than in the
control group. Overall, LGA delivery alone did not pre-
dict future MetS in women with normal glucose toler-
ance during pregnancy. In contrast, delivery of an LGA
infant in women with GDM predicts future risk of MetS
and thus risk for future cardiovascular disease.
Previously, only few studies have focused on the compo-
nents of MetS separately after an LGA delivery without
GDM. In our study, the mean waist circumference was
significantly greater in women with GDM at follow-up in
both birth weight categories. In addition, 81.3% of the
women with a prior LGA delivery without GDM exceeded
80 cm waist circumference limit fulfilling the compulsory
criterion of MetS. An explanation for this could be high
pre-pregnancy BMI in this study group and genetic sus-
ceptibility to such body composition. These results are in
agreement with a previous 18-years follow-up study show-
ing that waist circumference and fasting glucose were the
only significant components of MetS in mothers with
LGA infants with or without GDM during their pregnan-
cies [8]. In agreement with our results, no difference was
observed in waist circumference in women with macroso-
mic (> 4 kg) or stillborn newborns as compared to age-
and BMI-matched women without macrosomic deliveries
in a 9-year follow-up study in women without previous
GDM [19].
The development of dysglycemia and type 2 diabetes
in women with a background of GDM supported by a
large body of evidence [1, 2]. In accordance, a higher
percentage of fasting glucose > 5.6 mmol/l was detected
at follow-up in both GDM groups as compared to con-
trols regardless of the birth weight category. However,
no significant difference in fasting glucose was observed
in women with a previous LGA delivery without GDM
compared to controls. This is in agreement with a previ-
ous 2-year follow-up study, where fasting glucose levels
did not differ between the non-GDM women with previ-
ous LGA and AGA deliveries [20]. Moreover, a 9-year
follow-up study did not find any differences in fasting
glucose concentrations in women with and without pre-
vious macrosomic newborns with absence of GDM
during pregnancy [19].
In our study, LGA delivery without previous GDM did
not predict later dyslipidemia as compared to the
controls. Mean HDL cholesterol levels were lower and
triglycerides slightly higher in women with GDM in both
birth weight categories. However, concerning the lipid
components of MetS, only low HDL cholesterol was more
prevalent in the GDM groups than in controls. In agree-
ment with our findings, a study performed 2 years after
pregnancy revealed that no significant differences were
observed between 18 women with LGA infants and 18
women with AGA infants with respect to lipids [20]. Cor-
respondingly, a 9-year follow-up study demonstrated no
differences in the incidence of dyslipidemia between 570
women with a history of macrosomia or stillbirth without
GDM compared to age- and BMI-matched controls [19].
In contrast to these reports, a study of 48 women with
previous birth of large infants and without glucosuria
during pregnancy demonstrated that after 20–27 years
postpartum these women had significantly lower concen-
tration of HDL-cholesterol compared to age-, parity- and
BMI-matched controls with birth weight < 4500 g [21].
Further, a study of 332 women with a prior LGA delivery
reported lower HDL-cholesterol levels than in 2630
women with an appropriate-for-gestational-age (AGA)
newborns in an age-adjusted model 18 years after preg-
nancy [8]. However, when adjusted for confounders the
statistical significance was lost.
No studies have reported on the prevalence of the
MetS high blood pressure criterion (≥130/≥85 mmHg)
after an LGA delivery. We found no differences in this
prevalence between the study groups. In agreement with
our results, a prior macrosomic or LGA delivery in
women without GDM did not predict later increased
systolic or diastolic blood pressure in two-previous
follow-up studies [19, 21].
Although some previous research has been carried out
on components of MetS after an LGA delivery, the over-
all incidence of MetS has not been known. Our results
show that 54.4% of women with GDM and an LGA de-
livery developed incident MetS during the follow-up, as
compared to 43.6% in the AGA group. Interestingly, in
women without GDM, the incidence of MetS was not
higher with a previous LGA delivery as compared to the
group with AGA delivery even though maternal BMI
was higher in the LGA group. In this study, a consider-
able part of the women without GDM were overweight
(BMI ≥ 25 kg/m2) in pre-pregnancy: 28.7% in the AGA
and 51.1% in the LGA group (data not shown) as a re-
sult of risk-based screening for GDM. Therefore, it could
be assumed that an LGA delivery in women without
GDM is not predictive for later metabolic risk factors
and MetS. Similarly, no association between an LGA de-
livery with the calculated 10-year CVD risk after adjust-
ment for confounders was found in another study [8].
The strengths of the current study included the
long-term follow-up of a well-characterized cohort of
women, and the similar treatment received by all partici-
pants with GDM during pregnancy. It should be noted
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that in the present study, the GDM criteria in years 1989–
2008 were tight especially regarding the fasting glucose
value in OGTT. Thus, some women with GDM who
would not be diagnosed with GDM using the current cri-
teria were included as GDM women. This analysis has
concentrated on women who were chosen from an obstet-
ric population with risk factors for GDM potentially caus-
ing some selection bias. In addition, the study setting was
cross-sectional at the time of follow-up OGTT, not longi-
tudinal which would have been optimal to standardize the
protocol. Notwithstanding its limitations, this study does
suggest that even though all subjects have GDM risk fac-
tors, an LGA delivery does not predict later MetS in
women without GDM.
In conclusion, the women without GDM were at a
lower risk than those with GDM for MetS even with an
LGA delivery. This probably reflects good maternal vas-
cular health and its effects on birth weight. In contrast,
women with GDM and a previous LGA delivery should
be considered as a high-risk target group for prevention
of future MetS and CVD.
Conclusion
In summary, an LGA delivery without GDM was not
significantly associated with future maternal MetS risk
in the mean follow-up time of 7.3 years. High offspring
birth weight in this group is likely to be related to mater-
nal vascular health and genetic factors. In contrast,
women with GDM who have had an LGA delivery
should have a stringent follow-up after pregnancy to re-
duce the risk of future MetS and enhance women’s car-
diovascular health.
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